RxDoctor Payments DataLook up a doctor →

George Manoukian, MD

Clinical Cardiac Electrophysiology · Shenandoah, TXNPI 1619265485

Payments from drug & device makers

$3,242,794in general payments, 2019–2025

Across 1,569 payments — averaging $2066.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3.2M
  • Boston Scientific$25K
  • Biosense Webster, Inc.$17K
  • Medical Device Business Services, Inc.$6K
  • Medtronic$6K
  • Impulse Dynamics (USA) Inc.$5K
  • plus $8K from 19 others

What the payments were for

  • Consulting fees$190,15664%
  • Speaking & faculty fees$32,54511%
  • Travel & lodging$36,19812%
  • Food & beverage$36,15912%
  • Other$330%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,242,794 in reported general payments places this provider in the 95th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$321,560
Medicare patients
377
Services billed
1,953

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban226$200,575
XareltoRivaroxaban191$148,002
MultaqDronedarone Hcl112$129,739
Flecainide Acetate190$7,384
Amiodarone Hcl194$4,829
Dabigatran EtexilateDabigatran Etexilate Mesylate13$3,404
Mexiletine Hcl25$2,340
Metoprolol Succinate107$1,490
Diltiazem 24hr Er (Cd)Diltiazem Hcl70$1,039
Propafenone Hcl21$686
ClopidogrelClopidogrel Bisulfate96$674
Minocycline Hcl73$551
SotalolSotalol Hcl24$550
Digoxin28$422
Acetaminophen-CodeineAcetaminophen With Codeine55$256

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$145$148,002191 claims
Sanofi-aventis U.S. LLCMultaq$3,701$129,739112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in Shenandoah

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →